NDC 63323-322-41 - Imipenem and Cilastatin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-322
- Requested NDC
- 63323-322-41
- Package NDCs from labels
- 63323-322-21, 63323-322-93, 63323-322-41, 63323-322-94, 63323-322-01, 63323-322-25
- Manufacturer
- Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd
- Effective date
- 2022-10-11
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| IMIPENEM - Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | 2022-10-11 | HUMAN PRESCRIPTION DRUG LABEL |
| IMIPENEM - Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | 2022-10-10 | HUMAN PRESCRIPTION DRUG LABEL |
| IMIPENEM - Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | 2022-10-06 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-322-01 | Imipenem and Cilastatin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 20 | 12 | |
| 63323-322-25 | Imipenem and Cilastatin | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 12 | |
| 63323-322-41 | Imipenem and Cilastatin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 20 | 7 | |
| 63323-322-94 | Imipenem and Cilastatin | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 7 | |
| 63323-322-21 | Imipenem and Cilastatin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 20 | 5 | |
| 63323-322-93 | Imipenem and Cilastatin | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 5 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-322 | IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 12 | Current NDC, Legacy NDC, 2 package rows | 20221020_6ab0ca9e-9a79-4cab-9f09-470eda06952e.zip |
| 63323-322 | IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 7 | Current NDC, Legacy NDC, 2 package rows | 20221027_0a1dd9b9-ada1-4bff-9dcb-18961254e9e8.zip |
| 63323-322 | IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 5 | Current NDC, Legacy NDC, 2 package rows | 20221103_ce771566-c4f2-447e-944a-6b908925c90b.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-322-01 | EA - Each | 63323-322 | 34deeaf8-735f-4d5d-8ce0-f7bca735d05f | 1 | 2022-01-06 |
| 63323-322-20 | EA - Each | 63323-322 | 15d13752-d665-47b7-a49c-deac99c4cf15 | 1 | 2012-07-24 |
| 63323-322-21 | EA - Each | 63323-322 | f295eda5-5f73-456c-93a6-9c36771eb017 | 1 | 2022-04-06 |
| 63323-322-25 | EA - Each | 63323-322 | 3224fb37-f888-4ac9-943f-4fd3d043976d | 1 | 2013-02-13 |
| 63323-322-41 | EA - Each | 63323-322 | 1036c74b-ed3a-40f7-bbf1-87d3249cda17 | 1 | 2022-10-06 |
| 63323-322-93 | EA - Each | 63323-322 | 09ffc170-6c97-4df2-939c-49e83a8a41f7 | 1 | 2016-07-19 |
| 63323-322-94 | EA - Each | 63323-322 | 89f6cade-0bdd-4c18-b4ce-d0e9ff9c7655 | 1 | 2015-01-05 |
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Stomachin Antacid | MAGNESIUM CARBONATE AND SODIUM BICARBONATE | Chang Kuo Chou Pharmaceutical Co., Ltd. | 60fa0650-8785-4cb3-8f88-1a437296252f | 2026-11-02 | Warnings | 8MDF5V39QO |
| Arm and Hammer Baking Soda | SODIUM BICARBONATE | Church & Dwight Co., Inc. | 643fe204-4a7b-00e4-e053-2a91aa0aef06 | 2026-10-28 | Warnings | 8MDF5V39QO |
| Zegerid OTC | OMEPRAOLE, SODIUM BICARBONATE | Riley Consumer Care LLC | 8d00c19a-d86b-4a2f-8791-b320ad3ca781 | 2026-10-26 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate 10 gr | SODIUM BICARBONATE | GRAXCELL PHARMACEUTICAL, LLC | 897dbb09-fb47-4e03-8cae-bf76d48a7a03 | 2026-10-26 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate Antacid | SODIUM BICARBONATE | Rugby Laboratories | e73b5871-4a87-4473-ab00-5e5395be017d | 2026-10-16 | Warnings | 8MDF5V39QO |
| After Bite Advanced | SODIUM BICARBONATE | Tender Corporation d/b/a Adventure Ready Brands | 223d1de8-7940-bbdc-e063-6294a90a51d8 | 2026-10-16 | Warnings | 8MDF5V39QO |
| QUABIC-100 | HEMODIALYSIS GRADE SODIUM BICARBONATE SOLUTION | Aqua Medica, S.A. de C.V. | 1484a825-40c6-a9c9-e063-6294a90a9ca4 | 2026-10-16 | Warnings | 8MDF5V39QO |
| QUABIC-300 | HEMODIALYSIS GRADE SODIUM BICARBONATE SOLUTION | Aqua Medica, S.A. de C.V. | c3cd7f0f-8d70-23af-e053-2a95a90a569b | 2026-10-16 | Warnings | 8MDF5V39QO |
| QUABIC-100 | HEMODIALYSIS GRADE SODIUM BICARBONATE SOLUTION | Aqua Medica, S.A. de C.V. | 28152c9f-b15c-3707-e063-6394a90a70e9 | 2026-10-16 | Warnings | 8MDF5V39QO |
| SODIUM BICARBONATE | SODIUM BICARBONATE | Sun Pharmaceutical Industries, Inc. | 5ae65432-04a1-4b6b-8536-2535064fc782 | 2026-10-15 | Warnings, Adverse reactions | 8MDF5V39QO |
| Good Sense Omeprazole and Sodium Bicarbonate | OMEPRAZOLE, SODIUM BICARBONATE | L. Perrigo Company | bcf32242-de17-4da1-b707-4ce26262eb78 | 2026-10-14 | Warnings | 8MDF5V39QO |
| Sal De Uvas Picot | CITRIC ACID MONOHYDRATE, SODIUM BICARBONATE | Navajo Manufacturing Company Inc. | ff6ac79d-564d-4abf-83c7-b01751249c7f | 2026-10-09 | Warnings | 8MDF5V39QO |
| GoLYTELY | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Braintree Laboratories, Inc. | 57d22b0b-1ae0-4203-babc-f3bac17bd1c9 | 2026-10-08 | Warnings, Adverse reactions | 8MDF5V39QO |
| PEG-3350 and Electrolytes | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Affordable Pharmaceuticals, LLC | 448db7a5-1fea-4bf3-b1f5-e9d027a36603 | 2026-10-08 | Warnings, Adverse reactions | 8MDF5V39QO |
| PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride | POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE | Affordable Pharmaceuticals, LLC | 89ca6d56-527a-4be2-baea-531156f0a7be | 2026-10-08 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sal de Uvas Picot | CITRIC ACID MONOHYDRATE AND SODIUM BICARBONATE | Navajo Manufacturing Company Inc. | 5d6d297d-770b-dd9f-e063-6294a90a4bb8 | 2026-10-02 | Warnings | 8MDF5V39QO |
| Omeprazole/Bicarbonate | OMEPRAZOLE AND SODIUM BICARBONATE | Westminster Pharmaceuticals, LLC | d69c2f0f-4e8b-422a-8aaf-a825998b04e0 | 2026-09-25 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Major Pharmaceuticals | ebf340c9-0b6d-13d2-e053-2995a90ae338 | 2026-09-24 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate Antacid | SODIUM BICARBONATE | Rugby Laboratories | 28cdf049-acdb-4098-a5ca-e86257c81954 | 2026-09-24 | Warnings | 8MDF5V39QO |
| OMEPRAZOLE AND SODIUM BICARBONATE | OMEPRAZOLE AND SODIUM BICARBONATE | Aurohealth LLC | 224fe1a6-84e4-41eb-a328-1349f687f7f3 | 2026-09-22 | Warnings | 8MDF5V39QO |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.